Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T-MATE TCE anti-TROP2
- Development stage
- Preclinical
- Lead developer
- Amberstone Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
T-MATE TCE anti-TROP2 is a preclinical-stage bispecific T-cell engager (TCE) developed by Amberstone Biosciences using its proprietary Tumor-Microenvironment Activated ThErapeutic (T-MATE) platform. The drug is designed to target Trophoblast cell-surface antigen 2 (TROP2), a protein frequently overexpressed in various solid tumors, while minimizing systemic toxicity. It incorporates a pH-dependent CD3-binding domain that remains inactive at physiological pH but undergoes a conformational change to bind CD3 in the acidic conditions characteristic of the tumor microenvironment. This selective activation is intended to direct T-cell cytotoxicity specifically to tumor tissues, thereby reducing the risk of cytokine release syndrome (CRS) and on-target/off-tumor toxicities in healthy tissues where TROP2 is also expressed.
- Other names
- T-MATE anti-TROP2
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on T-MATE TCE anti-TROP2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T-MATE TCE anti-TROP2.